Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Ganglion Cysts 1Cluster Headache 1

Interventions

Cytarabine 32Cyclophosphamide 16Busulfan 16fludarabine phosphate 14Peripheral Blood Stem Cell Transplantation 13Filgrastim 13Idarubicin 11Etoposide 11Antilymphocyte Serum 10Cyclosporine 9Mitoxantrone 8Radiotherapy 7Methotrexate 7Daunorubicin 7Whole-Body Irradiation 5Tacrolimus 5Cord Blood Stem Cell Transplantation 5Clofarabine 5Mycophenolic Acid 4Methylprednisolone 4Flow Cytometry 4Arsenic Trioxide 4aldesleukin 3Topotecan 3Thiotepa 3Melphalan 3Imatinib Mesylate 3Gemtuzumab 3Cytogenetic Analysis 3Cyclosporins 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Megakaryoblastic, Acute × Idoxuridine × Clear all
NCT00003405 2021-10-14

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia

Rush University Medical Center

Phase 2 Withdrawn
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡